Mycosis fungoides primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
* There are no established measures for the secondary prevention of mycosis fungoides but recommended that effective measures for the [[secondary]] [[Prevention (medical)|prevention]] of mycosis fungoides is follow up [[Patient|patients]] with active or progressive [[disease]] | * There are no established measures for the secondary prevention of mycosis fungoides but recommended that effective measures for the [[secondary]] [[Prevention (medical)|prevention]] of mycosis fungoides is follow up [[Patient|patients]] with active or progressive [[disease]], every 4–6 weeks. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
* Effective measures for the secondary prevention of mycosis fungoides is follow up [[Patient|patients]] with active or progressive [[disease]] | * Effective measures for the secondary prevention of mycosis fungoides is follow up [[Patient|patients]] with active or progressive [[disease]], every 4–6 weeks.<ref name="WillemzeHodak2018">{{cite journal|last1=Willemze|first1=R|last2=Hodak|first2=E|last3=Zinzani|first3=P L|last4=Specht|first4=L|last5=Ladetto|first5=M|title=Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†|journal=Annals of Oncology|volume=29|issue=Supplement_4|year=2018|pages=iv30–iv40|issn=0923-7534|doi=10.1093/annonc/mdy133}}</ref> | ||
Revision as of 20:18, 21 December 2018
|
Cutaneous T cell lymphoma Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
- There are no established measures for the secondary prevention of mycosis fungoides but recommended that effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease, every 4–6 weeks.
Secondary Prevention
- Effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease, every 4–6 weeks.[1]
References
- ↑ Willemze, R; Hodak, E; Zinzani, P L; Specht, L; Ladetto, M (2018). "Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†". Annals of Oncology. 29 (Supplement_4): iv30–iv40. doi:10.1093/annonc/mdy133. ISSN 0923-7534.